NeuroSense Therapeutics Ltd. (NRSNW) Operating income 2021–2025
NeuroSense Therapeutics Ltd. (NRSNW) annual operating income history from SEC filings — each fiscal year as reported.
-$11.1MFY2025 · since FY2021: -$3.0M → -$11.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$11.1M | -11.9% |
| FY2024 | -$9.9M | +17.8% |
| FY2023 | -$12.0M | -14.2% |
| FY2022 | -$10.6M | -253.6% |
| FY2021 | -$3.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NRSNW financial trends
NRSNW RevenueNRSNW Net incomeNRSNW Net marginNRSNW Gross profitNRSNW Gross marginNRSNW Operating marginNRSNW Operating cash flowNRSNW Free cash flowNRSNW Capital expendituresNRSNW Return on equityNRSNW Stock buybacksNRSNW Dividends paidNRSNW Total assetsNRSNW Total liabilitiesNRSNW Shareholders’ equityNRSNW overview →